xenocoumacin 1: from Xenorhabdus; RN from Chem Abstr. Index Guide 1990; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 163752 |
| CHEMBL ID | 492201 |
| MeSH ID | M0194787 |
| Synonym |
|---|
| xenocoumacin 1 |
| CHEMBL492201 |
| 105688-01-5 |
| 4-amino-7-(diaminomethylideneamino)-2,3-dihydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl)-3-methylbutyl]heptanamide |
| 4-amino-7-((aminoiminomethyl)amino)-4,5,6,7-tetradeoxy-n-(1-(3,4-dihydro-8-hydroxy-1-oxo-1h-2-benzopyran-3-yl)-3-methylbutyl)heptonamide |
| heptonamide, 4-amino-7-((aminoiminomethyl)amino)-4,5,6,7-tetradeoxy-n-(1-(3,4-dihydro-8-hydroxy-1-oxo-1h-2-benzopyran-3-yl)-3-methylbutyl)- |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Both compounds exhibit antibacterial activity and potent antiulcer activity against stress-induced ulcers when dosed orally." | ( Biologically active metabolites from Xenorhabdus spp., Part 2. Benzopyran-1-one derivatives with gastroprotective activity. Akhurst, RJ; Gregson, RP; Lacey, MJ; McInerney, BV; Taylor, WC, ) | 0.13 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID337416 | Antimicrobial activity against Staphylococcus aureus V573 | |||
| AID337187 | Antimicrobial activity against Escherichia coli ESS | |||
| AID337408 | Antimicrobial activity against Salmonella Typhimurium CT10 | |||
| AID337414 | Antimicrobial activity against Sarcina lutea ATCC 8740 | |||
| AID337413 | Antimicrobial activity against Corynebacterium xerosis NCTC 9755 | |||
| AID337417 | Antimicrobial activity against Streptococcus pyogenes CN10 | |||
| AID337192 | Antimicrobial activity against Citrobacter freundii ES | |||
| AID337409 | Antimicrobial activity against Proteus mirabilis C977 | |||
| AID337415 | Antimicrobial activity against Staphylococcus aureus Oxford NCTC 6571 | |||
| AID337410 | Antimicrobial activity against Pseudomonas aeruginosa 1771P | |||
| AID337419 | Antimicrobial activity against Cryptococcus neoformans | |||
| AID337412 | Antimicrobial activity against Bacillus megaterium NCIB 9376 | |||
| AID337426 | Antiulcerogenic activity in stress-induced Wistar rat assessed as protection from ulcer at 25 mg/kg, po | |||
| AID337427 | Antiulcerogenic activity in stress-induced Wistar rat assessed as protection from ulcer at 10 mg/kg, po | |||
| AID337190 | Antimicrobial activity against Enterobacter cloacae N1 | |||
| AID337189 | Antimicrobial activity against Escherichia coli DCO | |||
| AID337411 | Antimicrobial activity against Acinetobacter lwoffii BRL 2400 | |||
| AID337191 | Antimicrobial activity against Klebsiella aerogenes A | |||
| AID337188 | Antimicrobial activity against Escherichia coli 10418 | |||
| AID337418 | Antimicrobial activity against Streptococcus sanguis ATCC 10556 | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||